U.S. Acne Drugs Market to Reach $1.94 Billion by 2027 at a CAGR of 9.63% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Acne Drugs Market Research Report by Acne Type (Comedonal, Cystic, and Inflammatory), Drug Class, Drug Type, Route of Administration, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The United States Acne Drugs Market size was estimated at USD 1,119.50 million in 2021, USD 1,266.86 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.63% to reach USD 1,943.71 million by 2027.

Report Contains:

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Acne Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers

5.1.2. Restraints

5.1.3. Opportunities

5.1.4. Challenges

6. Acne Drugs Market, by Acne Type

6.1. Introduction

6.2. Comedonal

6.3. Cystic

6.4. Inflammatory

6.5. Postsurgical/Wound

7. Acne Drugs Market, by Drug Class

7.1. Introduction

7.2. Antibiotics

7.3. Combination Drugs

7.4. Hormonal Agents

7.5. Retinoids

8. Acne Drugs Market, by Drug Type

8.1. Introduction

8.2. OTC Drugs

8.3. Prescription Drugs

9. Acne Drugs Market, by Route of Administration

9.1. Introduction

9.2. Injectable

9.3. Oral

9.4. Topical

10. California Acne Drugs Market

11. Florida Acne Drugs Market

12. Illinois Acne Drugs Market

13. New York Acne Drugs Market

14. Ohio Acne Drugs Market

15. Pennsylvania Acne Drugs Market

16. Texas Acne Drugs Market

17. Competitive Landscape

17.1. FPNV Positioning Matrix

17.2. Market Ranking Analysis

17.3. Market Share Analysis, By Key Player

17.4. Competitive Scenario

Companies Mentioned

• AbbVie Inc.
• Almirall, S.A.
• AndroScience Corporation
• Anterios Inc
• Bausch Health Companies Inc.
• Bayer AG
• BioPharmX, Inc
• Cipher Pharmaceuticals Inc.
• Daiichi Sankyo Company, Ltd
• F. Hoffmann-La Roche AG
• Foamix Pharmaceuticals Ltd.
• Galderma S.A.
• Guthy-Renker LLC
• Johnson & Johnson Services, Inc
• Mayne Pharma Group Limited
• Medicis Pharmaceutical Corporation
• Mylan N.V
• Oculus Innovative Sciences
• Pfizer Inc.
• Ranbaxy Laboratories Limited
• Skinvisible Pharmaceuticals
• Stiefel Laboratories, Inc
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd
• Valeant Pharmaceutical International Inc

For more information about this report visit https://www.researchandmarkets.com/r/41hgj4

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900